Evidence map›Paper›PMID 23162604›Full record

ArticleHepatitis monthly2012

The Predictive and Prognostic Significance of c-erb-B2, EGFR, PTEN, mTOR, PI3K, p27, and ERCC1 Expression in Hepatocellular Carcinoma.

Nuray Bassullu, Ilknur Turkmen, Murat Dayangac, Pinar Yagiz Korkmaz, Reyhan Yasar, Murat Akyildiz, Onur Yaprak, Yaman Tokat, Yildiray Yuzer, Gulen Bulbul Dogusoy

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Hepatitis monthly, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03203837 (Biomarker Analyses in Hepatocellular Carcinoma Patients Treated With Therasphere®), which is not on this map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03203837 terminatednot on this mapstarted 2017, after this paper: background citation

Biomarker Analyses in Hepatocellular Carcinoma Patients Treated With Therasphere®

TypeobservationalSponsorNorthwestern UniversityRan2017 to 2020Enrolled4ConditionsHepatocellular CarcinomaArmsPlasma collection
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 33 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Evidence-based complementary and alternative medicine : eCAM · 2022
    Article
  5. Review
  6. OncoTargets and therapy · 2021
    Article
  7. Article
  8. Precise Immunodetection of PTEN Protein in Human Neoplasia.Cold Spring Harbor perspectives in medicine · 2019
    Review
  9. Article
  10. Review
  11. Article
  12. Genetic alterations in hepatocellular carcinoma: An update.World journal of gastroenterology · 2016
    Review
  13. Article
  14. Article
  15. Article
  16. Active radar guides missile to its target: receptor-based targeted treatment of hepatocellular carcinoma by nanoparticulate systems.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015
    Review
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Nuray BassulluDepartment of Pathology, Istanbul Bilim University Medical Faculty, Istanbul, Turkey.
Ilknur Turkmen
Murat Dayangac
Pinar Yagiz Korkmaz
Reyhan Yasar
Murat Akyildiz
Onur Yaprak
Yaman Tokat
Yildiray Yuzer
Gulen Bulbul Dogusoy
Istanbul Florence Nightingale Hospital · TRIstanbul Bilim University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is the fifth most common fatal cancer and an important healthcare problem worldwide. There are many studies describing the prognostic and predictive effects of epidermal growth factor receptor 2 (c-erb-B2) and epidermal growth factor receptor 1 (EGFR), transmembrane tyrosine kinases that influence cell growth and proliferation in many tumors.

objectivesThe current study aimed to investigate the expression levels of c-erb-B2, EGFR, PTEN, mTOR, PI3K, p27, and ERCC1 in hepatocellular carcinoma (HCC) and their correlation with other clinicopathologic features. PATIENTS AND

methodsFifty HCC cases were stained immunohistochemically with these markers. Correlations between the markers and clinicopathologic characteristics and survival rates were analyzed.

resultsNo membranous c-erb-B2 staining was seen, whereas cytoplasmic positivity was present in 92% of HCC samples, membranous EGFR was observed in 40%, PI3K was found in all samples, and mTOR was seen in 30%, whereas reduced or absent PTEN expression was observed in 56% of samples and loss of p27 was seen in 92% of the cases. c-erb-B2 and mTOR overexpression, as well as reduced expression of p27, all correlated with multiple tumors (P = 0.041, P < 0.001, and P < 0.001, respectively). P27 loss, and mTOR and EGFR positivity were significantly correlated with AFP (P = 0.047, P = 0.004, and P = 0.008, respectively). Angiolymphatic invasion was more commonly seen in EGFR- and ERCC1-positive cases (P = 0.003 and P = 0.005). EGFR was also correlated with histological grade (P = 0.039). No significant correlations were found among PTEN , PI3K, and the clinicopathological parameters. Disease-free or overall survival rates showed significant differences among therapy modalities, AFP levels, angiolymphatic or lymph node invasions, and ERCC1 and p27 expression levels (P < 0.05).

conclusionsc-erb-B2, EGFR, mTOR, ERCC1 overexpression levels, and loss of p27 may play roles in hepatocarcinogenesis and may be significant predictors of aggressive tumor behavior. These markers were found to be correlated with certain clinicopathologic features, therapy modalities, and survival rates in the current study. These findings may help in planning new, targeted treatment strategies .

Indexed as

CarcinomaHepatocellularImmunohistochemistry

Identifiers

PMID23162604
PMCPMC3496900
OpenAlexW2122044186

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.